(EBS) Emergent Biosolutions - Performance 44.2% in 12m
Compare EBS with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-76.49%
#120 in Group
Rel. Strength
90.71%
#740 in Universe
Total Return 12m
44.22%
#25 in Group
Total Return 5y
-92.48%
#130 in Group
P/E -
(?) Percentile in Group
P/E Forward 16.7
70th Percentile in Group
PEG 1.55
87th Percentile in Group
FCF Yield 4.19%
83th Percentile in Group
12m Total Return: EBS (44.2%) vs XBI (-12.3%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
10.1% | 18% | 166% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
HLN NYSE Haleon |
14.3% | 31.2% | 47% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
AMGN NASDAQ Amgen |
-2.93% | -8.78% | 30.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
LONN SW Lonza |
9.55% | 9.34% | 30.4% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
BIM PA Biomerieux |
0.78% | 17.8% | -2.14% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
KMDA NASDAQ Kamada |
21.4% | 25.3% | -4.13% | 26.6 | 23.9 | 0.96 | 32.5% | 3.93% |
NBIX NASDAQ Neurocrine Biosciences |
34.3% | -15.5% | 3.48% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
ERF PA Eurofins Scientific SE |
20.4% | -0.39% | 7.63% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: EBS vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for EBS
Total Return (including Dividends) | EBS | XBI | S&P 500 |
---|---|---|---|
1 Month | 48.60% | 11.81% | 13.81% |
3 Months | -37.09% | -13.61% | -6.30% |
12 Months | 44.22% | -12.29% | 10.65% |
5 Years | -92.48% | -24.89% | 107.77% |
Trend Score (consistency of price movement) | EBS | XBI | S&P 500 |
1 Month | 70.2% | 72.9% | 83% |
3 Months | -79.7% | -83% | -75.3% |
12 Months | -13.5% | -51.6% | 50.1% |
5 Years | -89.6% | -53.9% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #128 | 32.9% | 30.6% |
3 Month | #192 | -27.2% | -32.9% |
12 Month | #26 | 64.4% | 30.3% |
5 Years | #137 | -90.0% | -96.4% |
FAQs
Does EBS Emergent Biosolutions outperforms the market?
Yes,
over the last 12 months EBS made 44.22%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.29%.
Over the last 3 months EBS made -37.09%, while XBI made -13.61%.
Over the last 3 months EBS made -37.09%, while XBI made -13.61%.
Performance Comparison EBS vs Indeces and Sectors
EBS vs. Indices EBS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 28.1% | 34.8% | -41.0% | 33.6% |
US NASDAQ 100 | QQQ | 27.9% | 31.2% | -41.2% | 32.6% |
US Dow Jones Industrial 30 | DIA | 27.7% | 38.6% | -40.7% | 36.5% |
German DAX 40 | DAX | 28.1% | 33.6% | -67.3% | 18.5% |
Shanghai Shenzhen CSI 300 | CSI 300 | 25.9% | 36.8% | -41.8% | 36.9% |
Hongkong Hang Seng | HSI | 24.9% | 28.7% | -49.4% | 30.5% |
India NIFTY 50 | INDA | 33.0% | 43.8% | -41.5% | 44.4% |
Brasil Bovespa | EWZ | 27.0% | 31.4% | -49.7% | 52.6% |
EBS vs. Sectors EBS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 27.5% | 35.2% | -48.1% | 22.7% |
Consumer Discretionary | XLY | 27.7% | 34.4% | -40.0% | 30.0% |
Consumer Staples | XLP | 29.0% | 42.0% | -48.0% | 35.1% |
Energy | XLE | 28.3% | 41.8% | -34.4% | 53.7% |
Financial | XLF | 27.0% | 35.1% | -48.1% | 21.8% |
Health Care | XLV | 31.1% | 47.7% | -36.0% | 48.3% |
Industrial | XLI | 26.4% | 31.8% | -42.5% | 33.2% |
Materials | XLB | 28.3% | 35.0% | -36.1% | 49.5% |
Real Estate | XLRE | 29.4% | 37.1% | -41.8% | 28.8% |
Technology | XLK | 27.0% | 27.4% | -38.1% | 37.1% |
Utilities | XLU | 28.0% | 39.0% | -48.7% | 26.8% |
Aerospace & Defense | XAR | 26.1% | 27.4% | -52.5% | 16.9% |
Biotech | XBI | 34.7% | 36.8% | -20.9% | 56.5% |
Homebuilder | XHB | 27.6% | 37.1% | -27.8% | 51.8% |
Retail | XRT | 26.2% | 34.0% | -36.8% | 45.7% |